What is claimed is:

/015/

1. A method for inhibiting, treating, or reducing unwanted side effects caused by a pharmaceutical composition including a drug and a solvent containing amphiphilic molecules, said method comprising employing a complement activation inhibitor in conjuction with said composition.

10

2. The method according to claim 1 wherein said amphiphilic molecule is polyethoxylated oil or a derivative thereof, emulsifiers or detergent molecules thereof.

15

3. The method according to claim 2 wherein said solvent is selected from the group consisting of hydrophilic or hydrophobic solvents that carry said amphiphilic molecules.

20

4. The method according to claim 3 wherein said solvent is Cremophor or Cremophor EL.

5. The method according to claim 1 wherein said drug is poorly soluble in water-based solvents and necessitates the addition of emulsifiers to become soluble.

6. The method according to claim 5 wherein said drug is selected from the group consisting essentially of: taxol, althesin, cyclosporin, diazepam, didemnin E, echinomycin, propandid, steroids, teniposide, and multivitamin products.

- 7. A pharmaceutical composition effective for inhibiting, treating, or reducing unwanted side effects caused by a drug composition including a drug and a solvent containing amphiphilic molecules in an individual, said pharmaceutical composition comprising a complement activation inhibitor in a pharmaceutically effective amount.
- 8. The phamaceutical composition of claim 7 wherein said solvent contains polythoxylated oil.
- 9. The pharmaceutical composition of claim 7
 wherein said complement activation inhibitor is
 selected from the group consisting of: sCR1, Factor H,

 Factor I, ClqInh, soluble forms of DAF, MCP,
 complestatin, and anti-C5a, compound K-76COOH,
 diamines, small polyanions, sulfonated aromatic
 compounds, small synthetic peptide analogues of the C
 terminal part of C3, CAB-2, indel-proximal peptides,
 serine esterase inhibitors, chimeric complement
 inhibitor proteins, and antibodies specific for
 complement proteins.

\$1.75 (2)

30

5

- 10. A method for preventing a complement activation reaction in an individual resulting from administration of a drug composition containing polyethoxylated oil, said method comprising any one of the steps selected from the group consisting of
 - (i) slowly infusing said drug composition,
- (ii) administering to said individual a high dose of a complement activation inhibitor prior to administration of said drug composition.
- 11. An in vitro method for predicting35 hypersensitivity reactions in an individual resulting

from a drug composition containing polyethoxylated oil, said method comprising incubating said drug composition with a sample of said individual's serum in vitro and detecting the presence or absence of complement activation.

1 d 3/

- 12. A method for inhibiting, treating, or reducing unwanted side effects caused by a pharmaceutical composition including a drug or active agent and a carrier containing amphiphilic molecules, said method comprising employing a complement activation inhibitor in conjuction with said composition.
- 13. The method according to claim 12 wherein said amphiphilic molecule is polyethoxylated oil or a derivative thereof.
- 14. The method according to claim 12 wherein said carrier is selected from the group consisting of liposomes, colloidal dispersions, particulate biomaterials, radiocontrast agents and emulsifierbased drug vehicles.
- 25 15. The method according to claim 12 wherein said drug is selected from the group consisting of antifungal, and anticancer drugs.
- 16. The method according to claim 15 wherein said drug is doxorubicin, daunorubicin, amphotericin B.
 - 17. The method according to claim 12 wherein said active agent is selected from the group consisting of hemoglobin, and polynucleotides.

- 18. A pharmaceutical composition effective for inhibiting, treating, or reducing unwanted side effects caused by a drug composition including a drug and a carrier containing amphiphilic molecules in an individual, said pharmaceutical composition comprising a complement activation inhibitor in a pharmaceutically effective amount.
- 19. The pharmaceutical composition of claim 18
 wherein said complement activation inhibitor is
 selected from the group consisting of: sCR1, Factor H,
 Factor I, ClqInh, soluble forms of DAF, MCP,
 complestatin, and anti-C5a, compound K-76COOH,
 diamines, small polyanions, sulfonated aromatic
 compounds, small synthetic peptide analogues of the C
 terminal part of C3, CAB-2, indel-proximal peptides,
 serine esterase inhibitors, chimeric complement
 inhibitor proteins, and antibodies specific for
 complement proteins.

25